**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | EP Lung Amsterdam | **Project Code** | PB5LEP027 |
| **Virtual Project Manager** | Choose an item. | **Clinical Program Manager** | Sanneke Koekkoek |
| **Compliance** | Susan Yarbrough | **Editor** | Trudy Stoddert |

**Launch Date/Internal Launch Date:**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

EP Lung Amsterdam Slides

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

**WEB URL:** www.primeoncology.com/eplung\_Amsterdam2015\_PDS

1. **[Insert Meeting Title]**

**prIME Downloadable Slides from the Expert Practicesm in Lung Cancer meeting in Amsterdam, the Netherlands**

**ACTIVITY FEATURES**

[Icon] Downloadable Slides

[Insert screen shot]

1. **ACTIVITY OVERVIEW**

prIME Oncology invites you to view downloadable slides from the Expert Practicesm in Lung Cancer meeting held in Amsterdam, the Netherlands, on 14 March 2015.

1. **PROVIDER**

This activity is provided by prIME Oncology.

1. **SUPPORTER**

Support for this educational activity is provided by F. Hoffmann-La Roche Ltd.

1. **[Tab—Lung Cancer] *for PDS***

Discussant: **Keith Kerr, MBChB, FRCPath,** Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Featured Topic: The role of pathology in the era of targeted therapy

Learning Objective: Evaluate lung cancer biomarkers to inform choice of treatment strategy for non-small cell lung cancer (NSCLC), including optimal methods for tissue sampling, analysis, and evaluation of results

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Enriqueta Felip, MD, PhD,** Vall d'Hebron University, Barcelona, Spain

Featured Topic: Keynote lecture—Immunotherapy: A step forward in treatment of advanced non-small cell lung cancer (NSCLC)

Learning Objective: Identify the role of immunotherapy in lung cancer, in particular the role of checkpoint inhibition, and evaluate efficacy and safety of these treatments in NSCLC

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Paul Van Schil, MD, PhD,** Antwerp University Hospital, Antwerp, Belgium

Featured Topic: Case #1—Stage III NSCLC: What’s the best multimodality approach?

*A surgical perspective*

Learning Objective: Adopt a multidisciplinary approach for the care of patients with lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Niels Reinmuth, MD, PhD,** Hospital Grosshansdorf, Grosshansdorf, Germany

Featured Topic: Case #1—Stage III NSCLC: What’s the best multimodality approach?

*A medical oncologist perspective*

Learning Objective: Adopt a multidisciplinary approach for the care of patients with lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Suresh Senan, MRCP, FRCR, PhD,** VU University Medical Center, Amsterdam, the Netherlands

Featured Topic: Case #1—Stage III NSCLC: What’s the best multimodality approach?

*A radiotherapist perspective*

Learning Objective: Adopt a multidisciplinary approach for the care of patients with lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Niels Reinmuth, MD, PhD,** Hospital Grosshansdorf, Grosshansdorf, Germany

Featured Topic: Case #2—Advanced NSCLC: Treatment strategies in the absence of targetable driver mutations

Learning Objective: Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Natasha Leighl, MD, MMSc, FRCPC,** Princess Margaret Hospital, Toronto, Canada

Featured Topic: Case #3—Adenocarcinoma with *ALK* rearrangement: Selecting optimal approach

Learning Objective: Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Francesco Grossi, MD,** National Institute for Cancer Research, Genoa, Italy

Featured Topic: Case #4—*EGFR*-mutated advanced NSCLC: Evaluating treatment options

Learning Objective: Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Natasha Leighl, MD, MMSc, FRCPC,** Princess Margaret Hospital, Toronto, Canada

Featured Topic: Case #5—Squamous cell lung carcinoma: The changing treatment paradigm

Learning Objective: Recognize the emerging treatment options for squamous cell NSCLC in order to provide best care for patients with these forms of lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**7. FACULTY**

Enriqueta Felip, MD, PhD

Vall d'Hebron University

Barcelona, Spain

Francesco Grossi, MD  
National Institute for Cancer Research  
Genoa, Italy

Keith Kerr, MBChB, FRCPath   
Aberdeen Royal Infirmary   
Aberdeen, United Kingdom

Natasha Leighl, MD, MMSc, FRCPC

Princess Margaret Hospital

Toronto, Canada

Niels Reinmuth, MD, PhD

Hospital Grosshansdorf

Grosshansdorf, Germany

Suresh Senan, MRCP, FRCR, PhD  
VU University Medical Center  
Amsterdam, the Netherlands

Paul Van Schil, MD, PhD

Antwerp University Hospital

Antwerp, Belgium

**8. TARGET AUDIENCE**

This educational activity is intended for European medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, and other healthcare professionals interested and/or involved in the treatment of patients with non-small cell lung cancer (NSCLC).

**9. LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

* Evaluate lung cancer biomarkers to inform choice of treatment strategy for NSCLC, including optimal methods for tissue sampling, analysis, and evaluation of results
* Identify the role of immunotherapy in lung cancer, in particular the role of checkpoint inhibition, and evaluate efficacy and safety of these treatments in NSCLC
* Adopt a multidisciplinary approach for the care of patients with lung cancer
* Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer
* Recognize the emerging treatment options for squamous cell NSCLC in order to provide best care for patients with these forms of lung cancer

**~~10. CONTINUING MEDICAL EDUCATION [if applicable]~~**

~~prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.~~

~~prIME Oncology designates this enduring activity for a maximum of XX~~ *~~AMA PRA Category 1 Credit(s)™.~~* ~~Physicians should claim only the credit commensurate with the extent of their participation in the activity.~~

**~~11. METHOD OF PARTICIPATION [if applicable]~~**

~~There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the~~ [~~Terms of Use.~~](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)

~~Links to the posttest are available on the video player pages.~~

~~In order to receive credit, participants must successfully complete the online posttest with XX% or higher.~~

**~~12. DISCLOSURES [if applicable]~~**

~~Insert disclosure info from the live meeting.~~

**14. MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**Insert presentation-specific text for the “View Activity” action item on the mobile app. *[copy from live meeting - the symposia webcast mobile app titles are exactly the same as the symposia app title (since once the live meeting has occurred, that title is no longer in use and it is easier for users to associate the enduring activity with the live activity that way.]*

1. **Web Activity Page Titles**

Landing Page Title: *Expert Practicesm in Lung Cancer*  
Activity Page Title: *[Presentation Titles]*

1. **Meta Description**

This educational activity features expert in the field discussing challenging clinical scenarios in lung cancer, highlighting the most up-to-date state of art approach and emerging data of novel therapeutic strategies, including ongoing clinical trials.

1. **Key Words and Key Phrases**

*NSCLC*

*Role of pathology of targeted therapy*

*Biomarker analysis*

*EGFR*

*ALK*

*KRAS*

*Driver mutations*

*HER2*

*BRAF*

*PIK3CA*

*AKT1*

*MAP2K1*

*MET*

*PDL1*

*Immunotherapy in advanced non-small lung cancer*

*Anti-CTLA4*

*Anti-PD1*

*Anti-PDL1multidisciplinary collaboration*

*Advanced NSCLC*

*Targetable driver mutations*

*EGFR-mutated advanced NSCLC*

*Adenocarcinoma*

*EML4-ALK*

*Squamous cell lung carcinoma*

*Felip*

*Kerr*

*Van Schil*

*Senan*

*Leighl*

*Grossi*

1. **~~[Meeting-Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included~~**

~~For each presentation:~~

~~Listing: City—Disease—Presenter~~

~~Description: [Name, degree(s)], from [Institution] discusses [insert topic description].~~

1. **E-blast Subject Header**

**PDS**: New prIME Downloadable Slides: Expert Practice in Lung Cancer